TY - JOUR
T1 - Simvastatin effect on high-sensitivity C-reactive protein in type 2 diabetes mellitus
AU - Prajitno, Jongky Hendro
AU - Soelistijo, Soebagijo Adi
AU - Pranoto, Agung
N1 - Publisher Copyright:
© Advanced Scientific Research. All rights reserved
PY - 2020
Y1 - 2020
N2 - Cardiovascular disease (CVD) as a complication of type 2 diabetes mellitus (T2DM) is associated with chronic low-grade inflammation. Statin has an anti-inflammatory effect that is marked by decreasing inflammatory marker, such as high-sensitivity C-reactive protein (hsCRP). This study aims to evaluate the administration of simvastatin in influencing hsCRP level in patients with T2DM. A randomized control study involving subjects with T2DM which divided into two groups was conducted. Pre- and post-treatment measurements of lipid profile, HbA1c, hsCRP were performed in both groups. Triglyceride and HbA1c levels were significantly different between two groups (p=0.001, p=0.016, respectively). Only HbA1c was significantly associated with pre-treatment hsCRP level (p = 0,006). After three months, statin group showed significantly lower hsCRP level than that before treatment (p=0.002). Moreover, pre- and post-treatment differences of hsCRP level in both groups were also significant (0.41±0.26 vs -0.13±0.32, respectively, p=0.003).Simvastatin could reduce inflammation in T2DM patients that was marked by decreasing level of hsCRP.
AB - Cardiovascular disease (CVD) as a complication of type 2 diabetes mellitus (T2DM) is associated with chronic low-grade inflammation. Statin has an anti-inflammatory effect that is marked by decreasing inflammatory marker, such as high-sensitivity C-reactive protein (hsCRP). This study aims to evaluate the administration of simvastatin in influencing hsCRP level in patients with T2DM. A randomized control study involving subjects with T2DM which divided into two groups was conducted. Pre- and post-treatment measurements of lipid profile, HbA1c, hsCRP were performed in both groups. Triglyceride and HbA1c levels were significantly different between two groups (p=0.001, p=0.016, respectively). Only HbA1c was significantly associated with pre-treatment hsCRP level (p = 0,006). After three months, statin group showed significantly lower hsCRP level than that before treatment (p=0.002). Moreover, pre- and post-treatment differences of hsCRP level in both groups were also significant (0.41±0.26 vs -0.13±0.32, respectively, p=0.003).Simvastatin could reduce inflammation in T2DM patients that was marked by decreasing level of hsCRP.
KW - High-sensitivity C-reactive protein
KW - Inflammation
KW - Simvastatin
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85083177164&partnerID=8YFLogxK
U2 - 10.31838/srp.2020.3.82
DO - 10.31838/srp.2020.3.82
M3 - Article
AN - SCOPUS:85083177164
SN - 0975-8453
VL - 11
SP - 618
EP - 623
JO - Systematic Reviews in Pharmacy
JF - Systematic Reviews in Pharmacy
IS - 3
ER -